New Zealand markets closed

Roche Holding AG (RHHBY)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
46.18-0.64 (-1.37%)
As of 12:38PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close46.82
Open46.36
BidN/A x N/A
AskN/A x N/A
Day's range45.88 - 46.40
52-week range39.72 - 51.05
Volume1,525,653
Avg. volume1,066,440
Market cap322.628B
Beta (5Y monthly)0.27
PE ratio (TTM)20.93
EPS (TTM)2.21
Earnings dateN/A
Forward dividend & yield1.22 (2.60%)
Ex-dividend date18 Mar 2021
1y target est52.44
  • GlobeNewswire

    Roche receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adults with RET fusion-positive advanced non-small cell lung cancer

    Gavreto showed robust and durable clinical responses in people with NSCLC with RET fusionsIf approved, Gavreto will be the first and only targeted treatment approved by the EMA that includes first-line treatment of people with RET fusion-positive advanced NSCLC Basel, 17 September 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Gavreto® (pralsetinib) as a mon

  • GlobeNewswire

    Roche opens access to pathology imaging tools to improve patient care

    Roche launches the Digital Pathology Open Environment, encouraging collaboration among software developers to improve patient outcomes and expand personalised healthcare through innovative image analysis tools Artificial intelligence technology shows promise in advancing pathology imaging, which can benefit cancer patients through more precise diagnosis leading to targeted treatmentOpen digital pathology environments can break down barriers to allow for rapid technology advances across industry

  • Zacks

    5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

    The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others